The FDA approved AstraZeneca’s Koselugo for children 1+ with NF1 and inoperable nerve tumors, expanding treatment options with an established safe dose.
The FDA approved AstraZeneca’s Koselugo for children 1+ with NF1 and inoperable nerve tumors, expanding treatment options with an established safe dose.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.